3272F Medial risk prostate cancer
Other
Also known as: intermediate-risk prostate cancer, moderate-risk prostate cancer, T2b-T3a or Gleason 7
Performance measure for prostate cancer classified as intermediate-risk disease. Quality metric documenting moderate-risk tumor characteristics for prognostic and treatment planning purposes.
Clinical Context
Quality measure used to stratify prostate cancer risk and guide multimodal treatment decisions, typically involving radiation with hormone therapy or surgical intervention.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.